{"id":"W4400914165","doi":"10.1016/j.jaad.2024.06.097","title":"Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Manitoba; University of Calgary; Lynde Centre for Dermatology; Université de Montréal; Heritage Medical Research Clinic; Probity Medical Research; Institute of Cosmetic and Laser Surgery; University of Toronto","funders":"LEO Pharma; Bausch Health; Coherus Biosciences; Glenmark Pharmaceuticals; Incyte; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Sanofi; Amgen; Concert Pharmaceuticals; Pfizer; Celgene; Galderma; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Alopecia areata; Medicine; Janus kinase; Janus kinase inhibitor; Hair loss; Dermatology; Randomized controlled trial; Hair growth; Safety profile; Janus; Pharmacology; Adverse effect; Internal medicine; Physiology; Nanotechnology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008979564,0.0002384942,0.002528681,0.0002425903,0.00005304672,0.00001170484,0.0002726415,0.0001161726,0.00000689555],"category_scores_gemma":[0.002128073,0.0001102021,0.0003447326,0.0005006892,0.001466642,0.0001406948,0.00005180669,0.0008904613,7.845319e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003759791,"about_ca_system_score_gemma":0.0003860494,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002545292,"about_ca_topic_score_gemma":0.00004668819,"domain_scores_codex":[0.9961045,0.001378393,0.001609992,0.000244828,0.0003829084,0.0002793409],"domain_scores_gemma":[0.9947394,0.003460491,0.001344242,0.0001683137,0.0001187842,0.0001688136],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9895919,0.0004997702,0.001180281,0.0000321959,0.0007195457,0.0001444688,0.002610019,0.0000156255,0.000322922,0.0001201348,0.000592288,0.004170845],"study_design_scores_gemma":[0.9867385,0.001813237,0.004303596,0.0007501165,0.0008628562,0.001140458,0.001553477,0.0004075264,0.001367091,0.0003291439,0.0006138689,0.0001201046],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9801563,0.002071485,0.00004808534,0.01545115,0.0001322215,0.001837297,0.00006232705,0.000009361656,0.000231747],"genre_scores_gemma":[0.9980365,0.0006807393,0.0002388413,0.0007824662,0.0002076624,0.00001894696,0.000006506712,0.00001966741,0.000008673017],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01788017,"threshold_uncertainty_score":0.5403903,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01082880236941663,"score_gpt":0.3073237314717573,"score_spread":0.2964949291023407,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}